BioMarin Pharmaceutical (BMRN) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

BioMarin Pharmaceutical Revenue Highlights

Latest Revenue (Y)

$2.42B

Latest Revenue (Q)

$733.87B

Main Segment (Y)

Product

Main Geography (Y)

UNITED STATES

BioMarin Pharmaceutical Revenue by Period

BioMarin Pharmaceutical Revenue by Year

Date	Revenue	Change
2023-12-31	$2.42B	15.42%
2022-12-31	$2.10B	13.53%
2021-12-31	$1.85B	-0.76%
2020-12-31	$1.86B	9.18%
2019-12-31	$1.70B	14.27%
2018-12-31	$1.49B	13.52%
2017-12-31	$1.31B	17.62%
2016-12-31	$1.12B	25.50%
2015-12-31	$889.89M	18.49%
2014-12-31	$751.04M	36.93%
2013-12-31	$548.49M	9.54%
2012-12-31	$500.72M	13.45%
2011-12-31	$441.36M	17.30%
2010-12-31	$376.27M	15.90%
2009-12-31	$324.66M	9.50%
2008-12-31	$296.49M	143.86%
2007-12-31	$121.58M	44.38%
2006-12-31	$84.21M	228.06%
2005-12-31	$25.67M	37.70%
2004-12-31	$18.64M	54.06%
2003-12-31	$12.10M	-13.07%
2002-12-31	$13.92M	18.98%
2001-12-31	$11.70M	-5.09%
2000-12-31	$12.33M	76.69%
1999-12-31	$6.98M	481.33%
1998-12-31	$1.20M	-

BioMarin Pharmaceutical generated $2.42B in revenue during NA 2023, up 15.42% compared to the previous quarter, and up 162.23% compared to the same period a year ago.

BioMarin Pharmaceutical Revenue by Quarter

Date	Revenue	Change
2024-09-30	$733.87B	103457.29%
2024-06-30	$708.66M	9.22%
2024-03-31	$648.83M	0.41%
2023-12-31	$646.21M	10.28%
2023-09-30	$585.97M	-1.45%
2023-06-30	$594.60M	0.28%
2023-03-31	$592.95M	10.31%
2022-12-31	$537.54M	6.37%
2022-09-30	$505.34M	-5.33%
2022-06-30	$533.80M	2.78%
2022-03-31	$519.36M	15.46%
2021-12-31	$449.81M	10.05%
2021-09-30	$408.74M	-18.53%
2021-06-30	$501.69M	3.22%
2021-03-31	$486.03M	7.50%
2020-12-31	$452.12M	-5.17%
2020-09-30	$476.78M	11.01%
2020-06-30	$429.49M	-14.46%
2020-03-31	$502.07M	10.48%
2019-12-31	$454.44M	-1.44%
2019-09-30	$461.10M	18.91%
2019-06-30	$387.76M	-3.24%
2019-03-31	$400.75M	13.46%
2018-12-31	$353.21M	-9.83%
2018-09-30	$391.71M	5.06%
2018-06-30	$372.85M	-0.16%
2018-03-31	$373.45M	4.23%
2017-12-31	$358.31M	7.23%
2017-09-30	$334.15M	5.26%
2017-06-30	$317.45M	4.51%
2017-03-31	$303.75M	1.22%
2016-12-31	$300.09M	7.22%
2016-09-30	$279.90M	-6.74%
2016-06-30	$300.13M	26.78%
2016-03-31	$236.74M	3.86%
2015-12-31	$227.94M	9.11%
2015-09-30	$208.90M	-16.61%
2015-06-30	$250.52M	23.25%
2015-03-31	$203.26M	-11.95%
2014-12-31	$230.85M	30.54%
2014-09-30	$176.85M	-7.79%
2014-06-30	$191.79M	26.55%
2014-03-31	$151.55M	3.19%
2013-12-31	$146.87M	7.31%
2013-09-30	$136.87M	0.05%
2013-06-30	$136.81M	6.94%
2013-03-31	$127.93M	-3.04%
2012-12-31	$131.94M	2.98%
2012-09-30	$128.12M	3.30%
2012-06-30	$124.02M	6.32%
2012-03-31	$116.65M	8.16%
2011-12-31	$107.85M	-4.92%
2011-09-30	$113.42M	2.53%
2011-06-30	$110.63M	1.07%
2011-03-31	$109.46M	7.72%
2010-12-31	$101.61M	3.95%
2010-09-30	$97.75M	6.31%
2010-06-30	$91.95M	8.24%
2010-03-31	$84.95M	-2.44%
2009-12-31	$87.08M	7.77%
2009-09-30	$80.81M	-2.39%
2009-06-30	$82.79M	11.90%
2009-03-31	$73.98M	-25.48%
2008-12-31	$99.28M	36.66%
2008-09-30	$72.65M	13.20%
2008-06-30	$64.17M	6.26%
2008-03-31	$60.40M	34.65%
2007-12-31	$44.85M	-

BioMarin Pharmaceutical generated $733.87B in revenue during Q3 2024, up 103457.29% compared to the previous quarter, and up 123422.38% compared to the same period a year ago.

BioMarin Pharmaceutical Revenue Breakdown

BioMarin Pharmaceutical Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Royalty And Other	$46.69M	$54.01M	$62.78M	$54.59M	$43.01M
Enzyme Product	$1.72B	-	-	-	-
Product	$2.37B	$2.04B	$1.78B	-	-
Product Two	-	-	-	-	$374.33M
Product Three	-	-	-	-	$463.35M
Product Six	-	-	-	-	$72.00M
Product Seven	-	-	-	-	$86.86M
Product Four	-	-	-	-	$544.35M
Product Five	-	-	-	-	$22.35M

BioMarin Pharmaceutical's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (57.34%), Enzyme Product (41.53%), and Royalty And Other (1.13%).

Quarterly Revenue by Product

Product/Service	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19
Royalty And Other	$11.87M	$9.90M	$11.02M	$13.06M	$13.06M	$10.58M	$9.99M	$12.05M	$12.00M	$16.14M	$13.83M	$14.59M	$14.90M	$15.02M	$18.26M	$15.07M	$16.04M	$10.45M	$13.03M	$17.86M
Product	$733.87M	$702.13M	$637.82M	$633.15M	$568.27M	$584.70M	$586.43M	$525.49M	$493.35M	$517.66M	$505.52M	$435.22M	$393.84M	$486.67M	$437.05M	$436.58M	-	-	-	-
Enzyme Product	-	-	-	$448.03M	$401.52M	$420.74M	$448.11M	-	-	-	-	-	-	-	-	-	-	-	-	-
Product Five	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$6.09M
Product Four	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$132.39M
Product Seven	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$31.61M
Product Six	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$25.18M
Product Three	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$122.58M
Product Two	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$94.87M

BioMarin Pharmaceutical's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Product (98.41%), and Royalty And Other (1.59%).

BioMarin Pharmaceutical Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 20	Dec 19	Dec 18
UNITED STATES	$912.38M	$778.44M	$696.79M
Rest Of World	$223.75M	$197.63M	$172.94M
Latin America	$205.86M	$218.79M	$185.05M
Europe	$518.47M	$509.19M	$436.43M

BioMarin Pharmaceutical's latest annual revenue breakdown by geography, as of Dec 20: UNITED STATES (49.04%), Europe (27.87%), Rest Of World (12.03%), and Latin America (11.07%).

Quarterly Revenue by Country

Country	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Dec 18	Sep 18	Jun 18	Mar 18
Latin America	$38.96M	$42.25M	$59.70M	$64.01M	$44.06M	$37.86M	$59.92M	$54.66M	$83.80M	$46.49M	$33.84M	$33.09M	$55.32M	$58.16M	$27.77M
Europe	$115.50M	$172.68M	$161.84M	$143.01M	$121.16M	$109.26M	$145.04M	$139.60M	$125.48M	$119.56M	$124.54M	$112.49M	$111.07M	$107.22M	$68.80M
Rest Of World	$58.05M	$82.52M	$56.30M	$62.39M	$58.61M	$49.81M	$52.94M	$43.96M	$49.94M	$52.30M	$51.43M	$38.92M	$50.59M	$44.68M	$82.33M
UNITED STATES	$196.24M	$204.25M	$208.19M	$182.70M	$252.95M	$232.55M	$244.17M	$216.22M	$201.87M	$169.41M	$190.94M	$168.71M	$174.72M	$162.79M	$124.14M

BioMarin Pharmaceutical's latest quarterly revenue breakdown by geography, as of Sep 21: UNITED STATES (48.01%), Europe (28.26%), Rest Of World (14.20%), and Latin America (9.53%).

BioMarin Pharmaceutical Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
INCY	Incyte	$3.70B	$962.99M
BMRN	BioMarin Pharmaceutical	$2.42B	$733.87B
EXEL	Exelixis	$1.83B	$478.06M
ALNY	Alnylam Pharmaceuticals	$1.83B	$420.15M
TECH	Bio-Techne	$1.16B	$289.46M
HALO	Halozyme Therapeutics	$829.25M	$290.08M
IONS	Ionis Pharmaceuticals	$787.65M	$225.25M
AMLX	Amylyx Pharmaceuticals	$380.79M	$416.00K
APLS	Apellis Pharmaceuticals	$366.28M	$176.57M
LEGN	Legend Biotech	$285.14M	$93.99M
BPMC	Blueprint Medicines	$249.38M	$128.18M
ARWR	Arrowhead Pharmaceuticals	$240.74M	-
AGIO	Agios Pharmaceuticals	$26.82M	$8.96M
LQDA	Liquidia	$17.49M	$4.45M
MREO	Mereo BioPharma Group	$10.00M	-
KRTX	Karuna Therapeutics	$654.00K	-
PCVX	Vaxcyte	-	-
DAWN	Day One Biopharmaceuticals	-	$20.07M

BMRN Revenue FAQ

What is BioMarin Pharmaceutical’s yearly revenue?

BioMarin Pharmaceutical's yearly revenue for 2023 was $2.42B, representing an increase of 15.42% compared to 2022. The company's yearly revenue for 2022 was $2.1B, representing an increase of 13.53% compared to 2021. BMRN's yearly revenue for 2021 was $1.85B, representing a decrease of -0.76% compared to 2020.

What is BioMarin Pharmaceutical’s quarterly revenue?

BioMarin Pharmaceutical's quarterly revenue for Q3 2024 was $733.87B, a 103457.29% increase from the previous quarter (Q2 2024), and a 125140.76% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $708.66M, a 9.22% increase from the previous quarter (Q1 2024), and a 19.18% increase year-over-year (Q2 2023). BMRN's quarterly revenue for Q1 2024 was $648.83M, a 0.41% increase from the previous quarter (Q4 2023), and a 9.43% increase year-over-year (Q1 2023).

What is BioMarin Pharmaceutical’s revenue growth rate?

BioMarin Pharmaceutical's revenue growth rate for the last 3 years (2021-2023) was 31.03%, and for the last 5 years (2019-2023) was 41.97%.

What are BioMarin Pharmaceutical’s revenue streams?

BioMarin Pharmaceutical's revenue streams in c 23 are Royalty And Other, Enzyme Product, and Product. Royalty And Other generated $46.69M in revenue, accounting 1.13% of the company's total revenue, down -13.56% year-over-year. Enzyme Product generated $1.72B in revenue, accounting 41.53% of the company's total revenue Product generated $2.37B in revenue, accounting 57.34% of the company's total revenue, up 16.19% year-over-year.

What is BioMarin Pharmaceutical’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of BioMarin Pharmaceutical was Product. This segment made a revenue of $2.37B, representing 57.34% of the company's total revenue.